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Abstract: A 39-year-old male with decreased visual acuity and extensive macular hemorrhage 
and edema secondary to a hemiretinal vein occlusion was treated with multiple intravitreal injec-
tions of bevacizumab 1.25 mg every four to six weeks for over one year. Treatment outcomes 
were assessed by visual acuity and Cirrus spectral domain optical coherence tomography. Treat-
ment resulted in ongoing visual and anatomic improvement, with resolution at the last visit.
Keywords: retinal vein occlusion, macular edema, bevacizumab
Introduction
Retinal vein occlusions are a frequent cause of visual loss, and approximately 16 million 
adults worldwide are affected.1 Macular edema and retinal ischemia are the primary 
sources of visual impairment in these settings. Retinal vein occlusions can be classi-
fied as branch retinal vein occlusion, hemiretinal vein occlusion, and central retinal 
vein occlusion depending on the occlusion site. Risk factors for the development of 
a retinal vein occlusion include diabetes mellitus, hypertension, hyperlipidemia, ath-
erosclerosis, glaucoma, and smoking.2
The clinical course and visual prognosis of retinal vein occlusions can be highly 
variable. Clinical trials have evaluated treatment modalities including observation, 
laser, intravitreal triamcinolone, and anti-vascular endothelial growth factor (VEGF) 
therapy. Intravitreal bevacizumab, an anti-VEGF drug, has been used to treat a   variety 
of vitreoretinal diseases. Rosenfeld et al first injected intravitreal bevacizumab for 
macular edema from a central retinal vein occlusion and also reported long-term 
improvements in visual acuity and optical coherence tomography (OCT, Carl Zeiss 
Meditec, Jena, Germany) being sustained through one year with treatment.3,4 More 
recently, randomized, controlled clinical trials have evaluated the frequency of treat-
ment with anti-VEGF therapy for macular edema secondary to retinal vein occlusions 
to help determine optimal long-term therapeutic strategies.5,6
We describe a case of an acute hemiretinal vein occlusion with confluent macular 
hemorrhage and persistent macular edema for which early and continued treatment 
with intravitreal bevacizumab facilitated functional and structural improvement and 
resolution.
Case report
A 39-year-old male with no significant past medical history presented with 
decreased vision in the left eye for six weeks. The patient was initially evaluated 
at an outside facility and diagnosed with a hemiretinal vein occlusion in the left 
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Figure 1 Initial presentation. Best corrected visual acuity 20/80. (A) Color fundus photograph demonstrates extensive, confluent inferior retinal hemorrhages with macular 
involvement. (B) Optical coherence tomography demonstrates intraretinal cysts and subretinal fluid. Central foveal thickness 696 microns (central 1 mm subfield). (C–E) 
Fluorescein angiography. (C) Early: 28 seconds, (D) 2.37 minutes, and (E) Late: 9.42 minutes, extensive blockage from hemorrhage and late hyperfluorescence.
eye. Medical and hypercoaguable laboratory evalua-
tion was unremarkable, and the patient was referred to 
the Bascom Palmer Eye Institute. Best corrected visual 
acuity was 20/20 in the right eye and 20/80 in the left 
eye. Intraocular pressures were 18 and 17 mmHg in the 
right and left eye, respectively. External and slit lamp 
examinations were unremarkable. Fundus evaluation of 
the right eye was within normal limits, and the left eye 
demonstrated extensive, confluent intraretinal hemor-
rhages extending inferiorly from the nerve and involv-
ing the macula (Figure 1A). OCT of the right eye was 
unremarkable, and the left eye demonstrated intraretinal 
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and subretinal fluid with a central retinal thickness of 
696 microns (Figure 1B). Fluorescein angiography of 
the left eye showed blockage from hemorrhage, with 
subsequent limited assessment of perfusion and late 
hyperfluorescence (Figure 1C–E). The patient was treated 
with 1.25 mg of intravitreal bevacizumab at this 
visit. At one month, visual acuity in the left eye improved 
to 20/60 and OCT demonstrated improved fluid with a 
central retinal thickness of 534 microns (Figure 2A). The 
patient was retreated with intravitreal bevacizumab. At the 
subsequent four-week visit, the patient was symptomatic 
with a decline in visual acuity to 20/70 and increased 
fluid was present on OCT (Figure 2B). The patient was 
treated with a third intravitreal bevacizumab injection. 
Six weeks later, visual acuity improved to 20/40, the 
confluent macular hemorrhage had improved, and OCT 
showed reduced fluid (Figure 2C and D). Treatment was 
continued at this visit, and at six-week intervals due 
to persistent visual symptoms and macular edema and 
  hemorrhage. The patient received a total of nine   intravitreal 
bevacizumab injections. At recent follow-up, six weeks 
after the last injection, visual acuity improved to 20/25 
and fundus evaluation showed minimal intraretinal hemor-
rhages (Figure 3A). OCT demonstrated a preserved foveal 
contour with resolved fluid and subfoveal inner and outer 
segment (IS/OS) disruption (Figure 3B). The patient was 
observed.
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Figure  2  Cirrus  spectral  domain  optical  coherence  tomography  progression.
(A) Best corrected visual acuity 20/60, improved intraretinal and subretinal fluid 
(central foveal thickness 534 microns) after initial intravitreal bevacizumab injection 
four weeks earlier. (B) Best corrected visual acuity 20/70, central foveal thickness 
682  microns.  (C)  Color  fundus  photograph  six  weeks  after  third  intravitreal 
bevacizumab injection. Improved confluent macular hemorrhage. (D) Best corrected 
visual  acuity  20/40,  central  foveal  thickness  473  microns,  corresponding  optical 
coherence tomography to (C) visit.
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Figure 3 recent follow-up. Best corrected visual acuity 20/25. (A) Color fundus 
photograph demonstrates resolution of majority of confluent hemorrhages. (B) 
Optical coherence tomography demonstrates resolved fluid (central foveal thickness 
261 microns) and presence of subfoveal inner and outer segment disruption.
Discussion
Macular edema is often a frequent cause of vision loss in 
patients with retinal vein occlusions. Since hemiretinal vein 
occlusions share etiologic and clinical features of both branch 
and central retinal vein occlusions, treatment strategies are 
often extrapolated from studies pertaining to these conditions. 
The Branch Vein Occlusion Study (BVOS) reported that laser 
photocoagulation is beneficial for perfused macular edema 
with ,20/40 vision for at least three months, but the visual 
recovery is both slow and limited.7 After three years of fol-
low-up, 63% of laser treated eyes improved $2 lines of vision 
  compared with 36% of control eyes.7 The average improvement 
of visual acuity was only 1.3 lines from the baseline in the 
laser-treated group, and 40% of eyes had a visual acuity 
of #20/40 and 12% had a visual acuity of ,20/200.7 Based 
on the Central Retinal Vein Occlusion Study (CVOS) results, 
grid laser photocoagulation is not a recommended therapy 
for improving visual acuity from macular edema secondary 
to central retinal vein occlusion.8 The Standard Care versus 
Corticosteroid for Retinal Vein Occlusion (SCORE) study 
group concluded that 1 mg intravitreal triamcinolone, with 
retreatment criteria as utilized in the trial, was superior to 
observation and could be considered up to one year for cen-
tral retinal vein occlusion-related macular edema, and was 
Table 1 Branch retinal vein occlusion summary data5,9,10
Treatment Months  BCVA  
changea
$15 lettersa CFT  
change
Triamcinolone  
1 mg (SCOrE)
12 +5.7 26% -149 microns
Dexamethasone  
0.7 mg (GENEVA)
6 +7.4 22% -119 microns
ranibizumab  
0.5 mg (BrAVO)
12 +18.3 60% -347 microns
Abbreviations: BCVA, best corrected visual acuity; CFT, central foveal thickness.
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equivalent to macular grid laser treatment for macular edema 
from a branch retinal vein occlusion (Tables 1 and 2).9,10 
This was the first trial to demonstrate efficacy of a treat-
ment for macular edema secondary to a central retinal 
vein occlusion. Further, the Ozurdex Geneva Study Group 
investigated the efficacy of a dexamethasone intravitreal 
implant, Ozurdex®, for the treatment of macular edema due 
to retinal vein occlusions. The proportion of eyes achiev-
ing at least a 15-letter improvement from baseline was 
significantly greater in the 0.35 mg and 0.7 mg implant 
groups from day 30; but this effect was not maintained by 
day 180, when no statistically significant difference from 
the sham group was observed (Tables 1 and 2).11 However, 
associated risks of intraocular pressure elevation and cataracts 
with steroid treatment were present in both studies.
Additional therapeutic modalities have also been 
explored in the treatment of macular edema from retinal 
vein occlusions. VEGF-A has been implicated as a major 
factor for increased vascular permeability, and elevated 
intravitreal VEGF levels have been reported to be signifi-
cantly increased after retinal vein occlusions and correlate 
with the degree of macular edema.12 VEGF also stimulates 
endothelial cell hypertrophy, which reduces capillary lumen 
size and may lead to retinal ischemia.13 Bevacizumab 
is a full length monoclonal humanized antibody to all 
active isoforms of vascular endothelial growth factor, and is 
frequently used in clinical practice to treat macular edema 
from retinal vein occlusions. Recently, clinical studies have 
demonstrated beneficial effects of monthly   intravitreal 
treatment with an anti-VEGF agent, ranibizumab, on 
both macular edema and visual acuity in patients with 
retinal vein occlusions. Data from the Phase III Study 
of the Efficacy and Safety of Ranibizumab Injec-
tion in Patients with Macular Edema Secondary to Branch 
Retinal Vein Occlusion (BRAVO) and the Study of the 
Efficacy and Safety of Ranibizumab Injection in Patients 
with Macular Edema Secondary to Central Retinal Vein 
Occlusion (CRUISE) demonstrated that a higher proportion 
of patients treated with ranibizumab 0.3 mg and 0.5 mg 
experienced significant improvements in visual acuity and 
central foveal thickness at six months following monthly 
dosing compared with patients who received sham injec-
tions (Tables 1, 2, and 3).5,6 These improvements were 
sustained at 12 months in both trials in the ranibizumab 
groups, following six months of as-needed treatment 
(Table 3).5,6 Overall, results from these studies demonstrate 
that regular, monthly anti-VEGF treatment for retinal vein 
occlusions provided improvements superior to previous 
treatment modalities.
In the current report, a young patient with decreased 
visual acuity and extensive macular hemorrhage with 
macular edema demonstrated an initial and ongoing 
functional and structural improvement with continued 
intravitreal bevacizumab treatment. Initial visual acuity, 
younger age, duration of retinal vein occlusion, baseline 
central retinal thickness, response to the first injection, and 
integrity of the photoreceptors have all been reported to be 
predictive factors for response to anti-VEGF therapy.14,15 
Although this patient returned to his baseline vision, the 
presence of subfoveal IS/OS disruption likely secondary 
to chronic macular edema and/or initial hemorrhage may 
also indicate that ongoing treatment with intravitreal beva-
cizumab prevented further destructive changes and a sub-
sequent decline in vision. The Patterns and Trends Survey 
by the American Society of Retina Specialists showed that 
approximately 50% of respondents use intravitreal beva-
cizumab as first-line therapy for retinal vein occlusions.16 
Table 2 Central retinal vein occlusion summary data6,9,10
Treatment Months BCVA  
changea
$15 lettersa CFT  
change
Triamcinolone  
1 mg (SCOrE)
12 -1.2 27% -196 microns
Dexamethasone  
0.7 mg (GENEVA)
6 +0.1 22% -119 microns
ranibizumab  
0.5 mg (CrUISE)
12 +13.9 51% -462 microns
Note: aETDrS letters.
Abbreviations: BCVA, change in best corrected visual acuity; CFT, change in 
central foveal thickness; EDTrS, Early Treatment for Diabetic retinopathy Study.
Table 3 Outcomes in BCVA and CFT after 6 and 12 months of ranibizumab 0.5 mg treatment in BrAVO and CrUISE studies5,6
Study Mean change from  
baseline BCVAa 0.5 mg  
at 6 months versus sham
Mean change from  
baseline CFT, μm  
at 6 months versus sham
Mean change from  
baseline BCVAa 0.5 mg  
at 12 months versus sham
Mean change from  
baseline CFT, μm  
at 12 months versus sham
BrAVO +18.3 versus +7.3 -345.2 versus -157.7 +18.3 versus +12.1 -374.4 versus -273.4
CrUISE +14.9 versus +0.8 -452.3 versus -167.7 +13.9 versus +7.3 -462.1 versus -427.2
Note: aETDrS letters. Patients were randomized 1:1:1 to receive sham injections or ranibizumab in one of two doses (0.3 or 0.5 mg) in both studies.
Abbreviations: BCVA, best corrected visual acuity; CFT, central foveal thickness; ETDrS, Early Treatment for Diabetic retinopathy Study.
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The favorable treatment outcome for this patient lends 
support to the clinical impression that regular injections 
of intravitreal bevacizumab are an effective primary treat-
ment strategy for persistent macular edema and hemor-
rhage from a hemiretinal vein occlusion.
Acknowledgment
This research was supported by an unrestricted award from 
Research to Prevent Blindness (P30EY014801).
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein 
occlusion: pooled data from population studies from the United States, 
Europe, Asia and Australia. Ophthalmology. 2010;117:313–319.
2.  Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic 
diseases associated with various types of retinal vein occlusion. Am J 
Ophthalmology. 2001;131:61–77.
3.  Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography 
findings after an intravitreal injection of bevacizumab (avastin) for 
macular edema from central retinal vein occlusion. Ophthalmic Surg 
Lasers Imaging. 2005;36:336–339.
4.  Gregori NZ, Gaitan J, Rosenfeld PJ, et al. Long-term safety and efficacy 
of intravitreal bevacizumab (avastin) for the management of central 
retinal vein occlusion. Retina. 2008;28:1325–1337.
5.  Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for 
macular edema following branch retinal vein occlusion: six month 
primary end point results of a Phase III study. Ophthalmology. 
2010;117:1102–1112.
6.  Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for 
macular edema following central retinal vein occlusion: six-month 
primary end points results of a phase III study. Ophthalmology. 
2010;117:1124–1133.
  7.  The Branch Vein Occlusion Study Group. Argon laser photocoagulation 
for macular edema in the branch vein occlusion. Am J Ophthalmology. 
1984;98:271–282.
  8.  The Central Vein Occlusion Study Group. Evaluation of grid pat-
tern photocoagulation for macular edema in central vein occlusion. 
The Central Vein Occlusion Study Group M report. Ophthalmology. 
1995;102:1425–1433.
  9.  The SCORE Study Research Group. SCORE study report 5: a random-
ized trial to compare the efficacy and safety of intravitreal injection(s) of 
triamcinolone acetonide with standard care to treat vision loss associated 
with macular edema secondary to central retinal vein occlusion. Arch 
Ophthalmol. 2009;127:1101–1114.
  10.  The SCORE Study Research Group. SCORE study report 6: a random-
ized trial to compare the efficacy and safety of intravitreal injection(s) of 
triamcinolone acetonide with standard care to treat vision loss associated 
with macular edema secondary to branch retinal vein occlusion. Arch 
Ophthalmol. 2009;127:1115–1128.
  11.  Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial 
of dexamethasone intravitreal implant in patients with macular edema 
due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.
  12.  Funk M, Kriechbaum K, Prager F, et al. Intraocular concentra-
tions of growth factors and cytokines in retina vein occlusion and 
the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 
2009;50:1025–1032.
  13.  Figueroa MS, Contreras I, Noval S, et al. Results of bevacizumab as 
the primary treatment for retinal vein occlusion. Br J Ophthalmol. 
2010;94:1052–1056.
  14.  Hoch AE, Ruppenstein M, Ach T, Dithmar S. OCT patterns of macular 
edema and response to bevacizumab therapy in retinal vein occlusion. 
Graefes Arch Clin Exp Ophthalmol. 2010;248:1567–1572.
  15.  Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, et al.   Predictors 
for short term visual outcome after anti-VEGF therapy of macular 
edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci. 
2011;52:3334–3337.
  16.  American Society of Retina Specialists Annual Preferences and Trends 
Survey, 2009. Available at: http://www.asrs.org. Accessed September 12, 
2011.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1513
Bevacizumab in hemiretinal vein occlusion